The FDA approval of GOMEKLI is a major achievement for SpringWorks Therapeutics, as it is the first approved treatment for NF1-PN in both adults and children. The positive Phase 2b trial results and the granting of a rare pediatric disease priority review voucher are likely to boost investor confidence and positively impact the stock price in the short term.